Core Insights - The company has achieved a breakthrough in research and development with the successful creation of a new technology platform called "Digital SAT + Fully Automated Equipment DigiNAT," which surpasses existing digital PCR technology in sensitivity, ease of use, and speed of detection [2] - The platform opens new pathways for precise RNA quantification detection and is expected to be applied in areas such as early cancer screening, infectious disease detection, and personalized medicine [2] - The company has initiated the development of RNA digital precision quantification detection products, focusing on urinary system tumor screening products for prostate cancer and bladder cancer [2] - The company is actively pursuing intellectual property protection around its core technology, with several domestic and international invention patents applied for, some of which have already been granted [2] - Additionally, the company's self-developed Chlamydia (CT) and Human Papillomavirus (HPV) testing reagents have successfully passed EU regulatory agency review and obtained IVDRCE certification, facilitating future international collaborations and expansion of overseas sales networks [2]

Core Viewpoint - The company, Rendu Biotech, reported a decline in revenue and net profit for the first half of 2025, but is focusing on technological innovation and international expansion to drive long-term growth [2][3][4]. Financial Performance - The company achieved operating revenue of 81.24 million yuan, a year-on-year decrease of 6.27% [2]. - The net profit attributable to shareholders was 2.038 million yuan, down 52.94% year-on-year [2]. - Despite challenges, the company saw over 50% year-on-year growth in sales of certain blood test products, particularly in the hepatitis B sector [2]. R&D and Innovation - The company has developed a new technology platform called "Digital SAT + Automatic Supporting Equipment DigiNAT," which offers significant advantages over traditional digital PCR technology [3]. - The company is focusing on RNA digital precision quantitative detection products, particularly in cancer screening and diagnosis, with ongoing development of prostate and bladder cancer tests [3]. - The global liquid biopsy market is expected to grow at a compound annual growth rate of over 20% in the next five years, with urine testing being one of the fastest-growing segments [3]. International Expansion - The company has made strides in international markets, signing contracts with users in the US, Japan, Indonesia, and Vietnam, and achieving its first sale in India [4]. - The company’s chlamydia (CT) and human papillomavirus (HPV) test kits received IVDR CE certification from a European Union notified body, allowing entry into the EU market [4]. - The certification highlights the company's strengths in product development and regulatory compliance, positioning it well for future international registrations [4].